Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.72 |
| ▸ | ACACA | Q13085 | 1/20 | 0.72 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.40 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28293184 | 0.92 | ACACB (0.75) | ACACBACACAFFAR1FFAR4ACLY | |
| SCHEMBL6180003 | 0.90 | ACACB (0.59) | ACACBACACAFFAR1FFAR4TBXAS1 | |
| SCHEMBL19159454 | 0.87 | ACACB (0.83) | ACACBACACAFFAR1FFAR4ACLY | |
| SCHEMBL186486 | 0.86 | ACACB (0.96) | ACACBACACAFFAR1FFAR4ACLY | |
| SCHEMBL205270 | 0.86 | ACACB (0.96) | ACACBACACAFFAR1FFAR4ACLY | |
| SCHEMBL6198099 | 0.85 | ACACB (0.50) | ACACBACACAFFAR1FFAR4TBXAS1 | |
| SCHEMBL23348922 | 0.84 | ACACB (1.00) | ACACBACACAFFAR1FFAR4ACLY | |
| Bempedoic Acid SCHEMBL185768 | 0.84 | ACACB (1.00) | ACACBACACAFFAR1FFAR4ACLY | |
| SCHEMBL186052 | 0.84 | ACACB (1.00) | ACACBACACAFFAR1FFAR4ACLY | |
| SCHEMBL19159252 | 0.84 | ACACB (0.77) | ACACBACACAFFAR1FFAR4ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003860-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2011-01-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003860-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | ACACB 543/4885ACACA 495/4885FFAR1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.